新股消息 | 麓鹏制药拟港股上市 中国证监会要求补充说明搭建离岸架构及返程并购的合规性等事项

Core Viewpoint - The China Securities Regulatory Commission (CSRC) has issued supplementary material requirements for 19 companies, including LUPENG Pharmaceutical, which is preparing for an IPO on the Hong Kong Stock Exchange, with CICC as the sole sponsor [1][2]. Group 1: Compliance and Regulatory Requirements - LUPENG Pharmaceutical is required to clarify the compliance of its offshore structure and backdoor listing, including details on foreign exchange management, overseas investment, and tax management [1]. - The company must provide a comprehensive overview of its major shareholders, including the complete ownership structure and any legal restrictions on shareholding [2]. - The CSRC has requested verification of the company's stock option incentive plan in accordance with regulatory guidelines [2]. Group 2: Domestic Operations and Financial Details - The company needs to explain the registered capital and actual contributions of its domestic operating entity, including any compliance issues related to capital contributions and share transfers [3]. - Progress on the regulatory compliance of LUPENG's domestic entity, specifically regarding its business scope and necessary licenses, must be detailed [3]. - The company is required to outline its plans for share splitting and the expected fundraising amounts, including the allocation of funds for domestic and international use [3][4]. Group 3: Product and Market Position - LUPENG Pharmaceutical is recognized as a leading global biopharmaceutical company with a proprietary drug development platform focused on high bioavailability oral drugs for cancer and autoimmune diseases [4]. - The core product, LP-168, is a dual BTK inhibitor in the NDA stage, showing significant clinical benefits and safety advantages over traditional BTK inhibitors [4].